ESPERITE (ESP): CEO Frederic Amar converts a portion of his Loan Note into 1.5 million shares.

January 8, 2018 Group News
blog_img2

ESPERITE (ESP): CEO Frederic Amar converts a portion of his Loan Note into 1.5 million shares.

Amsterdam, the Netherlands – 8 January 2018



PDF Downloads



ESPERITE N.V. (Euronext: ESP, ‘ESPERITE’, or ‘the Group’) declares the conversion of a portion of the EUR 2’025’000 loan note of CEO Frederic Amar into 1’500’000 shares as announced on 2 October 2017.

CEO Frederic Amar, confident in the development of the Group, maintains his stake at a strong level after the successive dilutive issuance of shares by L1 Capital.



About ESPERITE

ESPERITE is a diversified biotech global group leader in regenerative and precision medicine. Established in 2000, the holding group is headquartered in the Netherlands, listed at Euronext Amsterdam and Paris and operational in over 30 countries.

ESPERITE transforms the power of state-of-the-art technologies and scientific advancements into high quality products that bring the future of medicine to customers today at an affordable price.

To learn more about the ESPERITE group, or to book an interview with CEO Frederic Amar: +31 575 548 998 – ir@esperite.com or visit the websites at www.esperite.com www.genoma.com and www.cryo-save.com



This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).

With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State.

This press release and the information it contains do not, and will not, constitute an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of Esperite in the United States of America or any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), it being specified that the securities of Esperite have not been and will not be registered within the US Securities Act. Esperite does not intend to register securities or conduct a public offering in the United States of America.

Related Articles